Total health expenditure in Jordan accounted for 7.72% of the Jordanian GDP in 2011 in which about one third is spent on pharmaceuticals. Number of people with type2 diabetes is increasing in every country, in Jordan; the prevalence of diabetes in adult's ≥25 years of age is 17.1%, while an additional 7.8% of Jordanians have impaired glucose tolerance. The aim was to investigate the impact of adding one DPP-4 inhibitor as an oral hypoglycemic agent to the tender list of Jordanian MoH in the treatment of Type II DM. Quantities purchased by MoH in 2010 for oral hypoglycemic agents were used to calculate how many patients will be treated using these quantities. Annual cost of treating hypoglycaemia caused by oral hypoglycemics and their current acquisition cost were estimated. Costs of treating adverse effects were estimated based on MoH prices. Private pharmacy retail price for Vildaglaptin was used to estimate budget impact of adding this DPP-4 inhibitor to the treatment options for DM patients in the public sector. It was concluded that budget impact of adding Vildaglaptin to the tender list of MoH seems to have a very good potential of savings that is badly needed to treat more DM patients.
INTRODUCTION
Jordan is a small lower-middle income developing country with limited natural resources. The Gross Domestic Product (GDP) is 20.5 billion Jordanian Dinars (JDs) and per capita of GDP is 3275.8 JDs (2011) (1) . With an adult (>15 yrs) literacy rate of 93%, Jordan had a total unemployment rate of 12.2% in 2012 (2) .
Total health expenditure (THE) accounted for 7.72% of the Jordanian GDP in 2011 (approximately 1,581 billion JDs) and 252.9 JDs per capita healthcare spending; just below one third of this spent is on pharmaceuticals (27.07%); a high percentage compared to those of other developed countries and is more in line with countries in the Organisation for Economic Cooperation and Development (OECD) (3) . The Government of Jordan is committed to making quality health care services available and accessible to all citizens. The governance of the health care system in Jordan is vested in the Ministry of Health (MoH), in which governance within the MoH is highly centralized, and the main challenges facing the Ministry are improving efficiency, cost containment and quality of patient care. Because of the high percentage of spending on buying medicines, the pharmaceutical sector is considered a high priority to be looked at by the Jordanian MoH. The country's health care system is divided between public and private institutions. In the public sector, the MoH operates 1,245 primary health-care centres and 27 hospitals, accounting for 37 % of all hospital beds in the country; the military's Royal Medical Services runs 11 hospitals, providing 24% of all beds; and the Jordan University Hospital accounts for 3% of total beds in the country. The private sector provides 36 % of all hospital beds, distributed among 56 hospitals.
Being successful in dealing with communicable diseases and with its economic manifestations, the burden of disease in Jordan has shifted toward noncommunicable diseases (NCD) e.g. cardiovascular diseases such as Diabetes Mellitus (4) . Diabetes mellitus (DM) is a common chronic disease caused by an absolute lack of insulin or relative lack of insulin as a result of impaired insulin secretion and action. In the long term, these contribute to the development of macro and microcomplications such as cardiovascular disease (CVD), retinopathy, nephropathy, and neuropathy (5) . In addition, DM negatively impacted the emotional well being by more than 45% with a high level of distress leading to depression in some cases (6) . The latter increases the need to improve self management and psychological support for DM patients in order to improve their quality of life throughout their living long years. According to the International Diabetes Federation (IDF); 387 million people have diabetes in 2014 and by 2035 this will rise to 592 million worldwide. The number of people with type2 diabetes is increasing in every country, 77% of people with diabetes live in low-and middle-income countries and the greatest number of people with diabetes are between 40 and 59 years of age, 179 million people with diabetes are undiagnosed and Diabetes caused 4.9 million deaths in 2014 (7) . In Jordan, the prevalence of diabetes in adult's ≥25 years of age is 17.1%, while an additional 7.8% of Jordanians have impaired glucose tolerance with no significant differences between women and men (8) .
The overall goal of diabetes management is to achieve and maintain controlled blood glucose and reduce the risk of long-term complications. However; this is associated with an increased risk of hypoglycaemia; a common event occurs in 24% to 60% of diabetic patient (9) .
Hypoglycaemia is defined as abnormally low plasma glucose concentration which may expose the patients to potential harm; patients must be alerted to the risk of hypoglycaemia when plasma glucose ≤ 70 mg/dl (≤3.9mmol/L) (10) .
Hypoglycaemia is considered as a true medical emergency which requires immediate recognition and treatment to prevent organ and brain damage. It occurs suddenly and it's characterized by unpleasant physical and psychological symptoms such as shaking, sweating, drowsiness, nausea, poor motor coordination, mental confusion, negative mood, and unconsciousness (11) . The symptoms of hypoglycaemia depend on the duration and the severity of hypoglycaemia and varied from autonomic activation to behavioural changes to altered cognitive function to seizures or coma. Repeated hypoglycaemic episodes lead to compromise physiologic and behavioural defences against future falling glucose concentration, causing a cycle of recurrent hypoglycaemia (12) .
Antihyperglycemic therapy used for the management of diabetes can be associated with hypoglycaemia, a condition that has a substantial clinical impact, causing distress to affected individuals and impairing their ability to perform everyday activities. Furthermore, untreated hypoglycaemia can cause a significant economic and personal burden, so the identification and prevention of hypoglycaemia can reduce diabetes burden by prevention of hypoglycaemia complications (12) .
The aggressiveness of therapy to achieve glycemic control is considered as most important risk factor for hypoglycaemia. Other risk factors include glucoselowering medications, antecedent hypoglycaemia, alcohol, exercise and liver disease (13) . Over the time, symptoms of hypoglycaemia become less intense or even diminish altogether, resulting in hypoglycaemia unawareness in a significant proportion of diabetic patients, that is considered as important risk factor for severe hypoglycaemia (14) . On the other side, and because of all these, treating hypoglycemia resulted from those aggressive glycemic control including medications, is one of the costly interventions that increase the economic burden on the MoH pharmaceutical budget. Data from clinical trials in which Dipeptidyl peptidase-4 (DPP-4) inhibitors were employed as monotherapy or added to antidiabetic treatment indicate that the incretin-based therapies have very low risk for the development of hypoglycaemia (15) . The frequency of severe hypoglycemic events is the most important factor associated with fear of hypoglycemia; one of the obstacles to adherence to medications used to treat DM (16) . Both the frequency and the severity of hypoglycemia symptoms were associated with increase in worry of hypoglycemia and decreased quality of life among diabetic patients treated with a combination of metformin and sulfonylurea (17) .
To have an adequate glycemic control, there is a need not only for more effective therapeutic and educational approaches in management of diabetes, but also optimal allocation of resources by efficient use of scarce resources. The latter may include patient education regarding physical exercise and weight control, and decreasing the hypoglycemic fear of patients (18) .
The aim of this type of cost analysis was to investigate the impact of adding one DPP-4 inhibitor as an oral hypoglycemic agent to the tender list of Jordanian MoH in the treatment of Type II DM.
METHODOLOGY
Quantities purchased by MoH through its annual tender (2010) for oral hypoglycemic agents listed in the Jordanian National Drug Formulary (sulfonylureas: glimepiride 2 mg, glibenclamide 5 mg) were quantifiedbased on their winning prices-to how many patients will be treated using these quantities taking into consideration number of patients discontinue taking these medications compared to one DPP-4 inhibitor (Vildaglaptin) due to side effects (hypoglycemia, weight gain) and adherence.
Annual cost of treatment failure for those patients, cost of treating hypoglycaemia caused by oral hypoglycemics mentioned above and the current acquisition cost of them were estimated.
Local endocrinologist expert opinion elicitation combined with literature data (12) were used to determine all interventions required to treating mild, moderate and severe hypoglycemia. Costs of the latter were based on MoH prices in the public sector (19) . Acquisition cost in the private sector (pharmacy retail price) for Vildaglaptin was used to estimate budget impact of adding this DPP-4 inhibitor to the treatment options as an oral hypoglycemic for treating DM patients in the public sector (MoH). Average daily dose for one year treatment with Glimepiride is 4.5 mg (20) i.e. 4,000,000 X 2 mg / 4.5 mg = 1,777,778 tablets per year Number of patients treated by this amount annually is: 1,777,778 / 365 days = 4871 patients Discontinuation rate of glimepiride over vildagliptin is 3% (20) i.e. 3% of 4871 patients will not continue taking Average daily dose for one year treatment with Glibenclamide is 10 mg (twice daily) 15,000,000 X 5 mg/ 10 mg = 7,500,000 tablets per year Number of patients treated by this amount annually is: 7,500,000 / 365 = 20,548 patients Extrapolating the same 3% discontinuation rate of Glimepiride above (although glibenclamide side effects are more) for glibenclamide will lead to that: 3% X 20,548 = 616 patients Estimated number of events per 52 weeks (1 year) = 10 to zero for Glimepiride when compared to Vildagliptin i.e. 10 folds; 10 X 77 = 770 events (for those 77 patients) ii. Moderate hypoglycaemia = 7.3 % i.e. 282 patients Estimated number of events per 52 weeks (1 year) = 554 to 39 for Glimepiride when compared to Vildagliptin i.e. 14.2 folds; 14.2 X 282 = 4006 events (for those 282 patients) iii. Mild hypoglycaemia = 9% i.e. 348 patients iv. Estimated number of events per 52 weeks (1 year) = 554 to 39 for Glimepiride when compared to Vildagliptin i.e. 14.2 folds; 14.2 X 348 = 4942 events (for those 348 patients)  Treating hypoglycaemia (12) and ( fear of hypoglycaemia will negatively affect quality of life; but indirect costs will not be included) per each event yearly iii. Mild hypoglycaemia: no admission, once monthly follow up i.e. 12 consultant visits, 4 HbA 1 C, 365 FBS tests (N.B. fear of hypoglycaemia will negatively affect quality of life; but indirect costs will not be included) per each event yearly  Costs of treating hypoglycaemia as per MoH: (main direct medical costs only e.g. disposables were excluded i.e. direct non medical costs and indirect costs were not included) N.B. monthly employees deductions for health insurance were excluded, also it was assumed that always MoH facilities' capacity are enough to receive hypoglycaemic cases (19) . 
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